TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10630345

Group type: EXPERIMENTAL
Intervention: Hypnoanesthesia (HYP)
Number of subjects: 318

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 318
Study: 7549287

Group type: EXPERIMENTAL
Intervention: Formula enriched with omega-6 and omega-3 long-chain polyunsaturated fatty acids (LCP-F)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional infant formula without long-chain polyunsaturated fatty acids (F)
Number of subjects: 22
Study: 2184794

Group type: EXPERIMENTAL
Intervention: Labetalol (100 to 400 mg twice a day over a 6-week period)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 7259078

Group type: EXPERIMENTAL
Intervention: Althesin-halothane
Number of subjects: 187

Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 187

Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 187
Study: 30987667

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT) 3 g three times daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo 3 g three times daily for 8 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Sipjeondaebo-tang (SDT)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 27893018

Group type: EXPERIMENTAL
Intervention: ω-3 PUFAs (1.4 g daily) plus CBCM
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo (paraffin oil) plus CBCM
Number of subjects: 304
Study: 26448436

Group type: EXPERIMENTAL
Intervention: Take-out container provided during meal
Number of subjects: 50

Group type: COMPARATOR
Intervention: No take-out container provided (Control)
Number of subjects: 50
Study: 23577663

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation (Mini-HLM)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Off-pump coronary artery bypass (OPCAB)
Number of subjects: 120
Study: 21279664

Group type: EXPERIMENTAL
Intervention: Closure with small stitches (5-8 mm from wound edge, less than 5 mm apart)
Number of subjects: 691

Group type: COMPARATOR
Intervention: Closure with large stitches (more than 1 cm from wound edge)
Number of subjects: 691
Study: 18813219

Group type: EXPERIMENTAL
Intervention: Combination therapy (0.5 mg dutasteride + 0.4 mg tamsulosin once daily)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Dutasteride (0.5 mg once daily)
Number of subjects: 325

Group type: COMPARATOR
Intervention: Tamsulosin (0.4 mg once daily)
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 325
Study: 17499445

Group type: EXPERIMENTAL
Intervention: Personal alcohol feedback intervention
Number of subjects: 177

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 177
Study: 15501790

Group type: EXPERIMENTAL
Intervention: 25 microg of Vi-rEPA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 12.5 microg of Vi-rEPA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5 microg of Vi-rEPA
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vi-rEPA (all dosages)
Number of subjects: 46
Study: 11494441

Group type: EXPERIMENTAL
Intervention: Cerebrolysin (15 ml/day for 28 days)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9610787

Group type: COMPARATOR
Intervention: BB genotype
Number of subjects: 372

Group type: COMPARATOR
Intervention: Bb genotype
Number of subjects: 372
Study: 7740377

Group type: EXPERIMENTAL
Intervention: Rifater
Number of subjects: 106

Group type: COMPARATOR
Intervention: 4-drug regimen (isoniazid, rifampicin, pyrazinamide, ethambutol)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 106
Study: 3179149

Group type: EXPERIMENTAL
Intervention: Droperidol 5 mg i.v.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Droperidol 10 mg i.v.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Droperidol 15 mg i.v.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Neuroleptanalgesia
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Halothane or enflurane anaesthesia
Number of subjects: 42
Study: 31499249

Group type: EXPERIMENTAL
Intervention: Oral viscous budesonide (OVB)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Fluticasone from a multidose inhaler (MDI)
Number of subjects: 58
Study: 30635130

Group type: EXPERIMENTAL
Intervention: Betahistine (H3 receptor inverse agonist)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thioperamide (H3 receptor inverse agonist)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27993947

Group type: EXPERIMENTAL
Intervention: Disclosure of 10-year CHD risk based on conventional risk factors and genetic risk score (n=104)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional risk factors alone (n=103)
Number of subjects: 207
Study: 26370444

Group type: EXPERIMENTAL
Intervention: Phone coaching sessions (5 sessions of telephone-based counselling)
Number of subjects: 379

Group type: COMPARATOR
Intervention: Standard support
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Phone coaching sessions
Number of subjects: 379
Study: 23421438

Group type: EXPERIMENTAL
Intervention: Negative pressure ventilation (NPV) during exercise training
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no NPV)
Number of subjects: 36
Study: 21504304

Group type: EXPERIMENTAL
Intervention: Distally tapered, extended coated stem
Number of subjects: 50

Group type: COMPARATOR
Intervention: Straight, proximally coated stem
Number of subjects: 50
Study: 19466229

Group type: EXPERIMENTAL
Intervention: APF gel application for 1 min
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: APF gel application for 4 min
Number of subjects: 15

Group type: COMPARATOR
Intervention: Not treated (control)
Number of subjects: 15
Study: 16752874

Group type: EXPERIMENTAL
Intervention: Topical alprostadil (100 mcg)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Topical alprostadil (400 mcg)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study: 15223097

Group type: EXPERIMENTAL
Intervention: 12 mg buprenorphine in 24 h
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional doses of buprenorphine tapered down over 5 days
Number of subjects: 40
Study: 11330408

Group type: EXPERIMENTAL
Intervention: 45 g of native amylomaize starch, containing 28 g of resistant starch type II
Number of subjects: 23

Group type: COMPARATOR
Intervention: 45 g of maltodextrin (placebo)
Number of subjects: 23
Study: 9400788

Group type: EXPERIMENTAL
Intervention: Treatment group (specific treatment not detailed)
Number of subjects: 454

Group type: COMPARATOR
Intervention: Prednisone treatment group
Number of subjects: 454
Study: 8387254

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at 25 pmol/kg/min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion plus placebo inhalation
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo infusion plus albuterol inhalation (5 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP infusion (both rates)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ANP infusion at 25 pmol/kg/min
Number of subjects: 8
Study: 3318560

Group type: EXPERIMENTAL
Intervention: 1.1% lidocaine carbonate
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1.0% lidocaine hydrochloride
Number of subjects: 30
Study: 29937110

Group type: EXPERIMENTAL
Intervention: Tailored education by a student or pharmacist on how to read the label
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no tailored education)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Tailored education
Number of subjects: 92
Study: 27510396

Group type: COMPARATOR
Intervention: CPR with 100 compressions per minute (CPM)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR with 120 compressions per minute (CPM)
Number of subjects: 470

Group type: COMPARATOR
Intervention: CPR with 100 CPM
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: CPR with 120 CPM
Number of subjects: 470
Study: 25310117

Group type: EXPERIMENTAL
Intervention: Mother-infant pair clinics
Number of subjects: 1230

Group type: EXPERIMENTAL
Intervention: Mother-infant pair clinics plus SMS reminders
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 1230
Study: 22474993

Group type: EXPERIMENTAL
Intervention: L-carnitine for 2 weeks before ICSI
Number of subjects: 129

Group type: COMPARATOR
Intervention: ICSI alone (control group)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: L-carnitine followed by ICSI
Number of subjects: 129
Study: 21034597

Group type: EXPERIMENTAL
Intervention: Tongxinluo
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 219
Study: 18397683

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.5 microg/day)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Paricalcitol (1.5 microg/day)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 15851889

Group type: EXPERIMENTAL
Intervention: 50 mg meperidine
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 1 mg butorphanol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 25 mg meperidine plus 0.5 mg butorphanol
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 45
Study: 12360366

Group type: EXPERIMENTAL
Intervention: Combined hormone replacement therapy (0.625 mg/day conjugated equine estrogens combined with 2.5 mg/day medroxyprogesterone acetate)
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10000
Study: 10613728

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) treatment (3 x 10(6), 3 times a week, for 1 year) (n = 30)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Symptomatic treatment (n = 28)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (IFN) treatment
Number of subjects: 58
Study: 9093726

Group type: EXPERIMENTAL
Intervention: 6S-LV (100 mg/sqm/i.v.) + 5-FU (370 mg/sqm/15 min i.v. infusion) for 5 days every 28 days (arm A)
Number of subjects: 422

Group type: COMPARATOR
Intervention: 6S-LV (10 mg/sqm/i.v.) + 5-FU (doses as above) for 5 days every 28 days (arm B)
Number of subjects: 422

Group type: EXPERIMENTAL
Intervention: Both arms (A and B)
Number of subjects: 422
Study: 8239245

Group type: EXPERIMENTAL
Intervention: Aminophylline
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 3698513

Group type: EXPERIMENTAL
Intervention: Noradrenaline (NA) infusion for 3 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Angiotensin II (ANG II) infusion for 3 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (AVP) infusion for 3 hours
Number of subjects: 8
Study: 30541219

Group type: EXPERIMENTAL
Intervention: Supraglottic tracheal tube ventilation (group A)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Modified laryngeal mask airway (group B)
Number of subjects: 28
Study: 29424513

Group type: EXPERIMENTAL
Intervention: Modified Misgav-Ladach
Number of subjects: 137

Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr
Number of subjects: 137

Group type: COMPARATOR
Intervention: Kerr-half infraumbilical
Number of subjects: 137
Study: 24603562

Group type: EXPERIMENTAL
Intervention: Early supplementing enteral Microlipid (ML) and fish oil (FO)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 36
Study: 23016381

Group type: EXPERIMENTAL
Intervention: Unilateral pedicle screw fixation (uni-PS) with minimally transforaminal lumbar interbody fusion (TLIF)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Bilateral pedicle screw fixation (bi-PS) with posterior lumbar interbody fusion (PLIF)
Number of subjects: 102
Study: 20546511

Group type: EXPERIMENTAL
Intervention: Dysport (Botulinum toxin A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triamcinolone and lidocaine (TA group)
Number of subjects: 0
Study: 18537952

Group type: EXPERIMENTAL
Intervention: Sildenafil (initial dose 50 mg, adjustable to 25 or 100 mg)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Apomorphine (initial dose 2 mg, adjustable to 3 mg)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Preference after treatment
Number of subjects: 108
Study: 16318959

Group type: EXPERIMENTAL
Intervention: Sublingual buprenorphine (2 mg or 8 mg tablets; maximum daily dose: 8 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral methadone (racemic R-/S-methadone)
Number of subjects: 60
Study: 12556143

Group type: EXPERIMENTAL
Intervention: 6 mg/kg artemether, administered orally for a total of six doses once every 4 weeks
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo, administered orally for a total of six doses once every 4 weeks
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: 6 mg/kg artemether
Number of subjects: 322

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study: 10659911

Group type: EXPERIMENTAL
Intervention: Estroprogestin (E/P) pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months
Number of subjects: 102

Group type: COMPARATOR
Intervention: Gonadotrophin releasing hormone agonist (GNRHa) (tryptorelin 3.75 mg slow release every 28 days for 4 months) followed by E/P pill for 8 months
Number of subjects: 102
Study: 8968851

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet (25% CHO, n = 31)
Number of subjects: 68

Group type: COMPARATOR
Intervention: High carbohydrate diet (45% CHO, n = 37)
Number of subjects: 68
Study: 30772697

Group type: EXPERIMENTAL
Intervention: Gabapentin enacarbil (GBPen) at a fixed dose of 600 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29869298

Group type: EXPERIMENTAL
Intervention: 300 mg TQ Intermediate Aged
Number of subjects: 14

Group type: COMPARATOR
Intervention: 300 mg TQ Control
Number of subjects: 14
Study: 27534856

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily for 6 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Modafinil and Placebo
Number of subjects: 36
Study: 25099747

Group type: EXPERIMENTAL
Intervention: Symbiotic therapy (Group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No symbiotic therapy (Group B)
Number of subjects: 40
Study: 22057309

Group type: EXPERIMENTAL
Intervention: Fentanyl 1.5 μg/kg before induction, additional 50-μg boluses during anesthesia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Remifentanil 1 μg/kg infused in 10 min before induction, 0.1 μg/kg/min during anesthesia
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg infused in 10 min before induction, 1 μg/kg/h during anesthesia
Number of subjects: 84
Study: 18668472

Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Number of subjects: 63

Group type: COMPARATOR
Intervention: White Light Imaging
Number of subjects: 63
Study: 17285817

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Chloral hydrate
Number of subjects: 60
Study: 14639668

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 10

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 10
Study: 11078175

Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg twice daily for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9187896

Group type: EXPERIMENTAL
Intervention: Goretex sling
Number of subjects: 48

Group type: COMPARATOR
Intervention: Indigenous material graft (rectal fascia)
Number of subjects: 48
Study: 1396493

Group type: EXPERIMENTAL
Intervention: Systematic desensitization by clinical psychologists
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Systematic desensitization by clinical oncologists
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Systematic desensitization by oncology nurses
Number of subjects: 72

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 72
Study: 2412002

Group type: EXPERIMENTAL
Intervention: Dextran at 1 g/kg wt/24 hr for 5 days in addition to standard resuscitation and treatment
Number of subjects: 28

Group type: COMPARATOR
Intervention: Standard treatment (control group)
Number of subjects: 28
Study: 29343142

Group type: EXPERIMENTAL
Intervention: abobotulinumtoxinA, 500 U/2 mL dilution
Number of subjects: 134

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 134
Study: 27441684

Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (MEI)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Standard colonoscopy (without MEI)
Number of subjects: 334
Study: 23892190

Group type: EXPERIMENTAL
Intervention: Outside-in (Aris® transobturator sling system)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Inside-out (TVT™-O)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Overall (both groups)
Number of subjects: 66
Study: 22270202

Group type: EXPERIMENTAL
Intervention: Glyconate suture
Number of subjects: 48

Group type: COMPARATOR
Intervention: Poliglecaprone 25 suture
Number of subjects: 48
Study: 21041593

Group type: EXPERIMENTAL
Intervention: Obesity prevention program (group behavioral counseling to promote healthy eating and increased physical activity)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Alternative intervention (self-esteem and social efficacy)
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Obesity prevention program
Number of subjects: 303
Study: 18580512

Group type: EXPERIMENTAL
Intervention: Paco2 (IRMA)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Ptcco2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Petco2
Number of subjects: 34

Group type: COMPARATOR
Intervention: Paco2 (ABL625)
Number of subjects: 34
Study: 16647383

Group type: EXPERIMENTAL
Intervention: Cumulase (recombinant human-derived hyaluronidase)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hyase (bovine-derived hyaluronidase)
Number of subjects: 0
Study: 12803585

Group type: EXPERIMENTAL
Intervention: Preoperative recombinant human erythropoietin treatment (EPO group)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Autologous blood transfusion (control group)
Number of subjects: 38
Study: 10816223

Group type: EXPERIMENTAL
Intervention: Local administration of immunoglobulin G (IgG) intranasally daily for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo intranasally daily for 6 months
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Local administration of immunoglobulin G (IgG)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 8866410

Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 1 year (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhuEPO treatment for 2 years (Group B)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: rhuEPO treatment (both groups)
Number of subjects: 40
Study: 1641231

Group type: COMPARATOR
Intervention: Monovision (MV)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Soft diffractive (DIFF) bifocal contact lens
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Near center (CN) concentric bifocal design
Number of subjects: 15
Study: 6826412

Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) at 20.8 micrograms/min
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP) at 52.1 micrograms/min
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo solution
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nitroprusside (NTP)
Number of subjects: 12
Study: 30526539

Group type: EXPERIMENTAL
Intervention: Branded pack without HWL
Number of subjects: 656

Group type: COMPARATOR
Intervention: Plain pack with HWL
Number of subjects: 656

Group type: COMPARATOR
Intervention: Branded pack with HWL
Number of subjects: 656

Group type: COMPARATOR
Intervention: Plain pack (uniform color, brand imagery removed, standardized font)
Number of subjects: 656

Group type: EXPERIMENTAL
Intervention: Health warnings (5 text-based HWLs)
Number of subjects: 656
Study: 27449066

Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for neurofibromatosis (3RP‐NF)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Health Enhancement Program for NF (HEP‐NF)
Number of subjects: 63
Study: 23967878

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive Pacing Therapy (APT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specialist Medical Care (SMC)
Number of subjects: 0
Study: 22308558

Group type: EXPERIMENTAL
Intervention: Functional orthosis Neuro‐Lux (Sporlastic, Nürtingen, Germany) on top of usual care (n = 20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care alone (n = 21)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Functional orthosis usage
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Discomfort from orthosis
Number of subjects: 41
Study: 20731875

Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment pathways and diagnostic patterns
Number of subjects: 1064

Group type: EXPERIMENTAL
Intervention: Quality of life and psychological adjustment assessments
Number of subjects: 1064
Study: 18414712

Group type: EXPERIMENTAL
Intervention: Oral cannabinoid-containing medications (OCs)
Number of subjects: 191

Group type: COMPARATOR
Intervention: No intervention (nonrecipients)
Number of subjects: 191
Study: 15948779

Group type: EXPERIMENTAL
Intervention: Scleral buckling
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pars plana vitrectomy without buckling
Number of subjects: 50
Study: 12597947

Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg/day
Number of subjects: 43
Study: 11055145

Group type: EXPERIMENTAL
Intervention: Goal orientation with task difficulty
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Goal orientation with task consistency
Number of subjects: 388
Study: 8968305

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 40

Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 40
Study: 1453408

Group type: EXPERIMENTAL
Intervention: Mefenamic acid 500mg 3 times a day
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 4096214

Group type: EXPERIMENTAL
Intervention: Meibomian oils expressed onto the lid margins
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Topical anaesthesia
Number of subjects: 12
Study: 30475942

Group type: EXPERIMENTAL
Intervention: Prophylactic irradiation to the contralateral breast
Number of subjects: 162

Group type: COMPARATOR
Intervention: Standard loco‐regional treatment including surgery and radiation to the involved side
Number of subjects: 162